Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Horizon Therapeutics plc : Named to Newsweek's List of the Most Loved Workplaces for 2021

10/22/2021 | 09:30am EST

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named to Newsweek’s inaugural Most Loved Workplaces list for 2021, ranking among the top 100 companies recognized for employee happiness and satisfaction at work. Out of the companies recognized in the biotechnology and pharmaceutical category, Horizon ranked No. 1.

“At Horizon, our employees are at the heart of what we do which is why we are especially honored to be named to Newsweek’s Most Loved Workplaces,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Ensuring that employees share in our mission to support patients and the communities where we live and work drives our people-focused culture and remains a critical piece to our success.”

Produced in collaboration with the Best Practice Institute (BPI), a leadership development and benchmark research company, the Newsweek list results were determined after surveying more than 800,000 employees from businesses with workforces varying in size from 50 to more than 10,000. Companies were also evaluated by external public ratings from sites such as Comparably, Careerbliss, Glassdoor, Indeed and Google, and from direct interviews with and written responses from company officials. Newsweek then conducted additional research into every company on the list, as well as the top runners up, to determine the final list of 100 companies and their ranking.

“In the wake of the pandemic, business hit hurdles in terms of retaining and attracting employees – but the companies that made this list are delivering the respect, care, and appreciation that it takes to create a positive workplace that nurtures talent,” said Nancy Cooper, global editor in chief, Newsweek.

The full Newsweek list of 2021’s Most Loved Workplaces will be featured in the magazine’s Oct. 29 print edition and is currently available online.

About Newsweek

Newsweek is the modern global digital news organization built around the iconic, over 85-year-old American magazine. Newsweek reaches 100 million people each month with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia.

About Best Practice Institute

Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank, and solutions provider. BPI is the certifying body for Most Loved Workplace® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace®. BPI’s research proves that Most Loved Workplaces produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees.

About Horizon

Horizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.


© Business Wire 2021
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
11/22Horizon Therapeutics Says Phase 2/3 Data Support Efficacy of Uplizna in NMOSD Patients ..
MT
11/22New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficac..
BU
11/22Horizon Therapeutics plc Announces That A New Post Hoc Analysis of the UPLIZNA N-Moment..
CI
11/19Goldman Sachs Upgrades Horizon Therapeutics to Buy From Neutral; Price Target is $168
MT
11/15Horizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA (inebilizumab) as a..
AQ
11/15Horizon Therapeutics plc - New Real-World Data Show High Rate of Patient Adherence to T..
AQ
11/15Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week ..
BU
11/12Horizon Therapeutics Says Data Show 'High Rate of Patient Adherence' to Tepezza for Thy..
MT
11/12New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw)..
BU
11/12Horizon Therapeutics plc announces findings of a real-world adherence analysis of TEPEZ..
CI
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2021 3 196 M - -
Net income 2021 431 M - -
Net Debt 2021 1 097 M - -
P/E ratio 2021 55,8x
Yield 2021 -
Capitalization 23 154 M 23 154 M -
EV / Sales 2021 7,59x
EV / Sales 2022 5,76x
Nbr of Employees 1 805
Free-Float 98,0%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | HZNP | IE00BQPVQZ61 | MarketScreener
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 102,08 $
Average target price 142,91 $
Spread / Average Target 40,0%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman Chief Medical Officer & Executive Vice President
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY39.55%23 703
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049